Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.61−0.32 (-16.58%)
Close on Nov 12, 2026Market cap $313.17MP/E –Yield –
Altimmune EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Altimmune's EPS for the twelve months ending Sep 30, 2026 was -$0.71. For fiscal 2025 it was -$1.00. The highest annual figure on record is -$1.00 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.00 | – |
| FY2024 | Dec 31, 2024 | -$1.34 | – |
| FY2023 | Dec 31, 2023 | -$1.66 | – |
| FY2022 | Dec 31, 2022 | -$1.81 | – |
| FY2021 | Dec 31, 2021 | -$2.35 | – |
| FY2020 | Dec 31, 2020 | -$1.91 | – |
| FY2019 | Dec 31, 2019 | -$1.60 | – |
| FY2018 | Dec 31, 2018 | -$15.16 | – |
| FY2017 | Dec 31, 2017 | -$118.91 | – |
| FY2016 | Dec 31, 2016 | -$49.80 | – |
| FY2015 | Dec 31, 2015 | -$14.00 | – |
| FY2014 | Dec 31, 2014 | -$47.60 | – |
| FY2013 | Dec 31, 2013 | -$64.40 | – |
| FY2012 | Dec 31, 2012 | -$28.00 | – |
| FY2011 | Dec 31, 2011 | -$22.40 | – |
| FY2010 | Dec 31, 2010 | -$302.40 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.15 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.12 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.18 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.26 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.21 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.27 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.26 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.33 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.32 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.35 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.34 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.54 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.39 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.32 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.40 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.43 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.48 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.42 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.44 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.56 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.81 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.60 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.38 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.29 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.54 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.94 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.26 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.27 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.74 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.26 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.27 | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.73 | – |
| Q2 FY2018 | Jun 30, 2018 | -$10.29 | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.49 | – |
| Q4 FY2017 | Dec 31, 2017 | -$20.49 | -106.4% |
| Q3 FY2017 | Sep 30, 2017 | -$61.57 | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.80 | – |
| Q1 FY2017 | Mar 31, 2017 | -$20.40 | – |
| Q4 FY2016 | Dec 31, 2016 | $322.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?